Popular Articles

Agios Pharmaceuticals' Focus Of Drug Research - Cancer Metabolism - Selected For Stand Up To Cancer Grant
Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism "dream team" led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C"s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles" heel to target this deadly disease.
generic viagra online
Seniors Benefit From Strength Training
An updated Cochrane review finds that progressive resistance muscle training improves strength in older adults and enhances their ability to do daily tasks such as walking, climbing steps or getting out of a chair.
News of the day
Diabetes Specialists Call For Drug Regulators To Step In To Clarify Lantus Concerns, UK
BRITAIN"S top diabetes specialists added their weight to calls for European drug regulatory bodies to launch an urgent investigation into the popular insulin treatment glargine (Lantus). The move by the Association of British Clinical Diabetologists (ABCD) follows this week"s publication of four studies, which raise possible concern about an increased risk of the development of cancer in people who use this long-acting insulin therapy.
Cardiovascular

New York Times Examines Pilot Program To Fight Drug-Resistant TB In South African Communities

The New York Times examines a Doctors Without Borders pilot program to fight drug-resistant tuberculosis in South Africa that allows patients to stay in their homes rather than be isolated in hospital during treatment. The program, which is supported by the city of Cape Town and the Western Cape Province, aims to "show that such patients can be successfully treated in an impoverished community ò€¦ even while they are still infectious," the New York Times writes. Cheryl McDermid, a Canadian doctor with Doctors Without Borders, manages the program in the town of Khayelitsha. "About a fifth of the patients enrolled last year died, either while waiting weeks for a diagnosis or after treatment began. One in six of those who started treatment dropped out. But most patients have stuck with it and are now no longer infectious," the newspaper writes. McDermid said although it is still too early to know what the treatment success rate will be, there is no evidence that patients in the program are infecting the people who live with them. "Drug-resistant tuberculosis is a mounting global health threat," according to the newspaper. The disease is a "particularly virulent problem in Africa, where AIDS has heightened the vulnerability of millions," the New York Times writes. According to Paul Nunn, coordinator of the drug-resistance unit in the WHO"s TB department, ten African countries do not even have laboratories that can detect drug-resistant TB (Dugger, 7/28). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):